Thompson Davis & Co’s InMed Pharmaceuticals INM Stock Holding History

Thompson Davis & Co’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,025	Closed	-$22.4K	–	171
2025 Q3	$22.4K	Buy	+1,025	New	+$24.7K	0.01%	145

Other funds holding INM

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Thompson Davis & Co's INM Position: Q4 2025 in Review

Thompson Davis & Co sold out of InMed Pharmaceuticals (INM) in Q4 2025, closing a stake of 1,025 shares — an estimated $22.4K sold.

Thompson Davis & Co first reported a position in INM in Q3 2025 and held it in 1 quarter. The position peaked at $22.4K in Q3 2025. 6 funds tracked by Wall St. Rank hold INM as of Q4 2025.

Thompson Davis & Co reported no remaining InMed Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Thompson Davis & Co sold 1,025 InMed Pharmaceuticals shares in Q4 2025, an estimated $22.4K.
Thompson Davis & Co first reported a position in InMed Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Thompson Davis & Co's InMed Pharmaceuticals position peaked at $22.4K in Q3 2025.
6 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q4 2025.

Based on Thompson Davis & Co's 13F filing for Q4 2025, filed 12 Jan 2026.